Keyword Analysis & Research: compass pathways


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
compass pathways0.050.434901616
compass0.070.33280837
pathways0.170.2796518

Keyword Research: People who searched compass pathways also searched

Keyword CPC PCC Volume Score
compass pathways1.990.3124835
compass pathways stock0.920.4351497
compass pathways plc1.270.4931661
compass pathways stock price1.220.7182651
compass pathways news0.140.65571
compass pathways psilocybin0.480.895219
compass pathways careers1.470.8825316
compass pathways stock price today1.990.9612740
compass pathways plc stock1.330.426390
compass pathways stock forecast1.150.7117380
compass pathways aktie1.040.1804115
compass pathways share price1.930.3246284
compass pathways phase 31.140.17275
compass pathways clinical trials0.270.3183352
compass pathways market cap1.630.3317957
compass pathways yahoo finance1.070.322417
why is compass pathways stock down1.160.2973047
pathways compass health0.20.6350929

Search Results related to compass pathways on Search Engine

  • Compass Pathways | Biotechnology Company

    compasspathways.com

    https://compasspathways.com/

    WebMar 28, 2024 · Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa.

    DA: 65 PA: 36 MOZ Rank: 42

  • About psilocybin therapy | Compass Pathways

    compasspathways.com

    https://compasspathways.com/our-work/about-psilocybin-therapy-and-treatment/

    WebAbout psilocybin therapy. We are studying investigational psilocybin therapy (also known as psilocybin treatment), administered with psychological support, as a treatment for certain mental health conditions. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’.

    DA: 43 PA: 59 MOZ Rank: 16

  • Compass Pathways: COMP360 Psilocybin therapy administration …

    compasspathways.com

    https://compasspathways.com/psilocybin-therapy-216-patients/

    WebJun 28, 2021 · Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has completed psilocybin administration to the target 216 patients in its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant ...

    DA: 15 PA: 95 MOZ Rank: 15

  • Compass Pathways announces publication of phase 2b study of …

    compasspathways.com

    https://compasspathways.com/compass-pathways-announces-publication-of-phase-2b-study-of-comp360-psilocybin-therapy-for-treatment-resistant-depression-in-the-new-england-journal-of-medicine/

    WebNov 3, 2022 · This randomised, controlled, multicentre, double-blind phase 2b trial is the largest psilocybin therapy clinical trial ever conducted, with 233 patients from 10 countries in North America and Europe. 94% of the patients had no prior experience with psilocybin.

    DA: 64 PA: 8 MOZ Rank: 52

  • Compass Pathways announces positive topline results from …

    compasspathways.com

    https://compasspathways.com/positive-topline-results/

    WebNov 9, 2021 · Compass Pathways announces positive topline results from groundbreaking phase 2b trial of investigational COMP360 psilocybin therapy for treatment-resistant depression. Largest randomised, controlled, double-blind psilocybin therapy study ever completed. shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin.

    DA: 40 PA: 1 MOZ Rank: 27

  • Compass Pathways initiates UK component of global phase 3 …

    compasspathways.com

    https://compasspathways.com/compass-pathways-initiates-uk-component-of-global-phase-3-study-of-psilocybin-treatment-in-treatment-resistant-depression-and-launches-new-research-center/

    WebNov 15, 2023 · Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD).

    DA: 47 PA: 10 MOZ Rank: 5

  • COMPASS Pathways Receives FDA Breakthrough Therapy Designation …

    prnewswire.com

    https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html

    WebOct 23, 2018 · COMPASS Pathways is now running the first large-scale psilocybin therapy clinical trial for treatment-resistant depression, which will take place in Europe and North America over the next year or so.

    DA: 87 PA: 100 MOZ Rank: 42

  • Compass Pathways Announces Up to $285 Million Private …

    compasspathways.com

    https://compasspathways.com/compass-pathways-announces-up-to-285-million-private-placement-financing-joined-by-leading-healthcare-investors-2/

    WebAug 16, 2023 · Transaction led by healthcare specialist investors, TCGX and Aisling Capital. $125 million financing upfront with up to an additional $160 million tied to exercise of warrants. Net proceeds from financing expected to extend cash runway into late 2025. Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ...

    DA: 5 PA: 94 MOZ Rank: 82

  • Compass Pathways announces investigational COMP360 …

    yahoo.com

    https://finance.yahoo.com/news/compass-pathways-announces-investigational-comp360-210500418.html

    WebDec 19, 2023 · Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder. Compass Pathways. Tue, Dec 19, 2023, 1:05 PM 6 min read.

    DA: 8 PA: 25 MOZ Rank: 51

  • Compass Pathways announces investigational COMP360 …

    compasspathways.com

    https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-investigational-comp360-psilocybin

    WebPDF Version. December 19, 2023. Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder. Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions.

    DA: 47 PA: 69 MOZ Rank: 29